American Capital Management Inc. Grows Position in Repligen Co. (NASDAQ:RGEN)

American Capital Management Inc. lifted its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 12.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 379,034 shares of the biotechnology company's stock after acquiring an additional 42,335 shares during the quarter. Repligen makes up 1.8% of American Capital Management Inc.'s portfolio, making the stock its 24th biggest position. American Capital Management Inc. owned 0.68% of Repligen worth $56,408,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. Swedbank AB bought a new position in Repligen in the 1st quarter worth $5,518,000. First Turn Management LLC bought a new position in Repligen in the third quarter worth about $13,202,000. Banque Pictet & Cie SA lifted its holdings in Repligen by 74.6% in the second quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company's stock worth $4,351,000 after buying an additional 14,746 shares during the period. Geneva Capital Management LLC boosted its position in Repligen by 8.5% during the 3rd quarter. Geneva Capital Management LLC now owns 138,677 shares of the biotechnology company's stock valued at $20,638,000 after acquiring an additional 10,908 shares in the last quarter. Finally, Diversified Trust Co grew its holdings in shares of Repligen by 3.7% during the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock worth $372,000 after acquiring an additional 106 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Stock Up 0.4 %

Shares of NASDAQ:RGEN traded up $0.55 during trading on Friday, reaching $150.54. 225,812 shares of the stock traded hands, compared to its average volume of 700,387. The stock has a market cap of $8.43 billion, a P/E ratio of -406.85, a price-to-earnings-growth ratio of 4.53 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a 50-day moving average of $140.98 and a two-hundred day moving average of $142.41. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million for the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 EPS. As a group, sell-side analysts expect that Repligen Co. will post 1.52 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research firms have recently commented on RGEN. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price on the stock. Benchmark reiterated a "hold" rating on shares of Repligen in a research note on Monday, August 5th. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating for the company. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.